Press releases
- RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren's Syndrome
- RemeGen Celebrates World Lupus Day 2024 with Increased Lupus Visibility through Vital Knowledge Sharing
- RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome
- RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024
Key statistics
On Monday, RemeGen Co Ltd (REGMF:PKC) closed at 4.00, -13.04% below its 52-week high of 4.60, set on Jun 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.00 |
---|---|
High | 4.00 |
Low | 4.00 |
Bid | -- |
Offer | -- |
Previous close | 4.00 |
Average volume | 1.00k |
---|---|
Shares outstanding | 544.33m |
Free float | 307.55m |
P/E (TTM) | -- |
Market cap | 22.13bn HKD |
EPS (TTM) | -3.03 HKD |
Data delayed at least 15 minutes, as of May 20 2024 14:30 BST.
More ▼